Clinical trials
Progressive Disease clinical trials
Below are recruiting progressive disease clinical trials, each written for real people, not researchers. We’re tracking 200 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07316452Recruiting
Early heart disease risk study for adults under 45
This study looks at what makes heart disease progress in younger adults (18 to 45). If you have symptoms of heart disease and have had a heart CT scan, joining this research might help doctors better predict and manage your condition.
BeijingAges 18–45 - NCT07362225Recruiting
MPN Progress Registry: Tracking Symptoms and Progression
This observational registry tracks symptoms, treatments, and disease changes over time in people diagnosed with myeloproliferative neoplasms (MPNs). By joining, you help doctors learn more about the condition and possibly contribute to better future care.
Chicago, IllinoisAges 18 years+ - NCT07392411Recruiting
AI study of face and speech in Parkinson's disease
This study uses artificial intelligence to analyze facial expressions and speech patterns in people with Parkinson's disease, multiple system atrophy, or progressive supranuclear palsy. The goal is to find digital markers that may help track the disease.
Beijing, Beijing MunicipalityAges 15–75 - NCT07611136Recruiting
Brain Vessel Disease Progression After Different Stroke Types
This study examines how small blood vessel disease in the brain progresses differently depending on whether you've had a recent stroke. Researchers will use MRI scans to track changes over time and better understand this condition.
Ulm, Baden-WurttembergAges 18 years+ - NCT07152197Recruiting
Resistance Exercise for Charcot-Marie-Tooth Disease
This trial tests whether resistance exercises (like lifting weights with your legs) can help people with Charcot-Marie-Tooth disease. It is for young adults aged 15 to 29 who can move their ankle enough to do strength training.
Temuco, La AraucaníaAges 15–29 - NCT06567990Recruiting
Type 2 diabetes and fatty liver: new tests for disease tracking
This study is looking for people with type 2 diabetes and fatty liver disease to find better ways to track how the disease progresses. They will use special tests (biomarkers) to see if the liver is getting worse over time.
DijonAges 40–80 - NCT07136844Recruiting
Walking and arm movement study for nerve and muscle conditions
This study uses motion analysis to understand walking and arm function in adults with certain neurological or metabolic diseases. The goal is to find patterns that help doctors better manage these conditions.
LiègeAges 18 years+ - NCT07723872Recruiting
Finger vs. earlobe oxygen test during a 6-minute walk
This study compares oxygen levels measured at the finger versus the earlobe during a 6-minute walk test for people with interstitial lung disease. It helps find the most accurate way to monitor your oxygen during exercise.
Granollers, SpainAges 18 years+ - NCT00091871Recruiting
Understanding familial high eosinophil disease in families
This study follows families with a genetic condition that causes high levels of white blood cells called eosinophils. Researchers want to understand how the disease develops and changes over time to help predict who may get worse and how to treat it better.
Bethesda, MarylandAges 1–100 - NCT06602934Recruiting
Pneumonia, heart health, and your body's germs
This study looks at how pneumonia affects the long-term health of your heart and lungs by studying the germs that live in your body. It may help doctors understand why some people get worse and how to better protect your heart after a serious infection.
AngersAges 18–80 - NCT07237685Recruiting
Diabetes and heart artery plaque progression study
This study uses a follow-up CT scan of your heart arteries to see how diabetes-related plaque buildup changes over time. It may help researchers understand how well current diabetes treatments are protecting your heart.
AmsterdamAges 18 years+ - NCT06440746RecruitingPhase 2/Phase 3
Testing olokizumab for progressive lung scarring diseases
This trial tests a drug called olokizumab to see if it can slow down worsening lung scarring (fibrosis) in people with certain types of progressive interstitial lung diseases. It's for patients whose lung function has declined despite current treatments.
BarnaulAges 18 years+ - NCT06675864RecruitingPhase 1/Phase 2
YTB323 for non-active progressive MS
This trial tests a new treatment called YTB323, which is a type of personalized cell therapy (CAR-T) designed to target your immune system and slow down MS progression. It is for people with non-active progressive MS who have seen their disability worsen recently.
Darlinghurst, New South WalesAges 18–60 - NCT06040073Recruiting
Study of heart artery blockages after heart attack
This study is for people who recently had a heart attack and need an angiogram. It looks at blockages that are not completely blocking blood flow to learn how they change over time.
BeijingAges 18 years+ - NCT04954820RecruitingPhase 2
Second round Lutathera for intestinal NET after regrowth
This Phase 2 study looks at whether giving Lutathera again (a second round) can control an intestinal neuroendocrine tumor (NET) that came back or progressed after the first treatment. It mainly targets adults whose scan shows tumors still take up the right “target” signal and who previously benefited for at least 12 months.
AngersAges 18 years+ - NCT06601998Recruiting
Heart health after severe pneumonia
This study looks at how heart health changes in people who have recovered from severe pneumonia, including COVID-19. It compares survivors to healthy people and those with heart risk factors.
AlexandroupoliAges 18 years+ - NCT06083363Recruiting
Recovery after severe lung infection
This study follows patients who had severe pneumonia or acute respiratory distress syndrome (ARDS) in the intensive care unit (ICU) to understand how they recover over time. It aims to identify factors that affect recovery trajectories.
Tortosa, TarragonaAges 18 years+ - NCT05272371RecruitingPhase 1
Dinutuximab beta plus chemo for childhood neuroblastoma after relapse
This Phase 1 trial tests a combination of dinutuximab beta (an immunotherapy) and chemotherapy in children with high-risk neuroblastoma that did not respond to standard treatment or has come back or progressed. It aims to see how well the treatment works and how safely it can be given in this situation.
Krakow, MalopolskaAges 1–18 - NCT04966481RecruitingPhase 3
Palbociclib plus cetuximab versus cetuximab alone
This trial studies whether adding palbociclib to cetuximab works better than cetuximab by itself for head and neck cancer that is growing again after an anti–PD-1/PD-L1 treatment. It is for people whose tumor has a specific gene change (CDKN2A loss) and who have not had too many prior treatments.
Worthington, MinnesotaAges 18 years+ - NCT02363595Recruiting
Genetic clues for how small thyroid cancers may grow
This study looks at gene changes to predict whether a small papillary thyroid cancer found on biopsy is likely to stay stable or grow over time. It may help doctors choose who can safely stay on watchful waiting.
New York, New YorkAges 18 years+ - NCT07651540Recruiting
Understanding Sensory Nerve Damage: The Neuronoscore Study
This study helps doctors better understand and measure sensory nerve damage (nerves that feel pain, temperature, and touch). You may qualify if you have a specific type of nerve damage caused by cancer, autoimmune disease, platinum chemotherapy, or a rare genetic condition.
AngersAges 18 years+ - NCT06378892RecruitingPhase 2
Study of chemo plus lorlatinib for ALK+ lung cancer
This trial tests combining chemotherapy with lorlatinib for people with ALK-positive lung cancer that has spread outside the brain while on lorlatinib. The goal is to see if adding chemo can help control the cancer when it starts growing again.
AvianoAges 18 years+ - NCT06079567Recruiting
Study of FSHD2 progression over 18 months
This study follows people with FSHD2 over 18 months to learn how the disease progresses and affects daily life. No new drugs are tested—just regular check-ups and an MRI scan.
LeuvenAges 18–75 - NCT05584397Enrolling by invitation
Compare immune activity and HIV hidden reservoir on two treatments
This study compares how active the immune system is and how large the “hidden” HIV reservoir is in people on two different HIV treatment types. It may help researchers understand whether staying on a tenofovir-containing regimen leads to better control of HIV hiding in the body.
Seattle, WashingtonAges 18–65
Hear when a new Progressive Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for progressive disease?
- Yes. Clin2 currently lists 200 recruiting progressive disease studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a progressive disease trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a progressive disease trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.